The full funding of the pivotal Phase 3 trial removes a major near-term financial overhang and increases the probability of clinical success. Traders should monitor for interim data readouts expected next year, which could support an early approval pathway. The Fast Track designation may accelerate regulatory review if the trial is successful.
Price Chart
Executive Summary
MAIA Biotechnology announced that its recent $33 million capital raise is expected to fully fund the ongoing pivotal Phase 3 trial of ateganosine, its telomere-targeting anticancer therapy for non-small cell lung cancer (NSCLC). The FDA has granted Fast Track designation for the drug in third-line NSCLC treatment.
Key Facts
- MAIA Biotechnology raised $33 million through a public offering of common stock in March 2026
- Net proceeds are expected to fully fund the ongoing pivotal Phase 3 trial (THIO-104) of ateganosine for NSCLC
- FDA has granted Fast Track designation for ateganosine in third-line NSCLC treatment
- The Phase 3 trial is a global, multicenter, open-label, randomized study comparing ateganosine plus checkpoint inhibitor to chemotherapy in up to 300 patients
- Interim data from the Phase 3 trial is expected next year and may support a discussion with the FDA for early full commercial approval
Financial Impact
The $33 million capital raise provides full funding for the pivotal Phase 3 trial of ateganosine
Risk Factors
- Clinical trial may not meet primary endpoints
- Interim data may not support early approval discussion with FDA
- Dilution from the $33 million common stock offering
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-015662 |
| Exhibit: ex99-1.htm | 0001493152-26-015662 |
| Document: 0001493152-26-015662-index-headers.html | 0001493152-26-015662 |
| Document: 0001493152-26-015662-index.html | 0001493152-26-015662 |
| Document: 0001493152-26-015662.txt | 0001493152-26-015662 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 20d ago | EFFECT | $1.18 | awaiting T+60 | — | $1.18 (+0.00%) |
Oct 6, 2026 21d ago | 8-K | $1.19 | awaiting T+60 | — | $1.18 (−0.84%) |
Sep 25, 2026 4w ago | S-3 | $1.18 | awaiting T+60 | — | $1.18 (+0.00%) |
Sep 16, 2026 5w ago | Press Release | $1.40 | awaiting T+60 | — | $1.18 (−15.71%) |
Sep 15, 2026 6w ago | Press Release | $1.34 | awaiting T+60 | — | $1.18 (−11.94%) |
Sep 15, 2026 6w ago | Insider Cluster | $1.34 | awaiting T+60 | — | $1.18 (−11.94%) |
Jun 3, 2026 20w ago | Press Release | $1.43 $1.38 | ▼ −3.50% | ▼ −6.00% | $1.18 (−17.48%) |
Jun 2, 2026 21w ago | Insider Cluster | $1.35 $1.39 | ▲ +2.96% | ▲ +1.85% | $1.18 (−12.59%) |
May 19, 2026 23w ago | DEFA14A | $1.23 $1.34 | ▲ +8.94% | ▲ +2.65% | $1.18 (−4.07%) |
May 14, 2026 23w ago | 8-K | $1.26 $1.38 | ▲ +9.52% | ▲ +5.01% | $1.18 (−6.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers